Autolus Therapeutics (Nasdaq: AUTL) granted equity awards under its 2025 Inducement Plan to 13 new employees, consistent with Nasdaq Listing Rule 5635(c)(4).
The awards cover options for 25,420 ADSs at a $1.66 exercise price and 87,530 RSUs, with four-year vesting tied to continued service.
Loading...
Loading translation...
Positive
Inducement grants support hiring of 13 employees under 2025 plan
25,420 stock options and 87,530 RSUs align employee incentives with shareholders
Stock options priced at $1.66, matching June 23, 2026 closing price
Negative
Equity awards totaling 112,950 shares may incrementally increase share count
This announcement outlines modest inducement equity awards of 25,420 options and 87,530 RSUs to 13 n...
Analysis
This announcement outlines modest inducement equity awards of 25,420 options and 87,530 RSUs to 13 new employees, using market-priced options. With an effective $150,000,000 shelf and low short interest, future capital-raising steps remain a key watch point.
Key Figures
Stock options granted:25,420 ADSRSUs granted:87,530 RSUsEmployees receiving grants:13 employees+5 more
8 metrics
Stock options granted25,420 ADSInducement stock option awards to new employees under 2025 Inducement Plan
RSUs granted87,530 RSUsInducement restricted stock units to new employees under 2025 Inducement Plan
Q1 2026 results with strong revenue growth but sizable net loss and restructuring.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news-driven moves have generally aligned with the tone of the announcements, with clinical and award news lifting the stock and earnings pressure weighing on shares.
"granted as an inducement material to the individual becoming an employee of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
american depositary sharesfinancial
"granted stock option awards to purchase an aggregate of 25,420 American Depositary Shares and 87,530 restricted stock units"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
restricted stock unitsfinancial
"25,420 American Depositary Shares and 87,530 restricted stock units (RSUs), each representing an equal number of ordinary shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
exercise pricefinancial
"The stock option awards have an exercise price of $1.66 per share, which is equal to the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
LONDON & GAITHERSBURG, Md., July 01, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 25,420 American Depositary Shares and 87,530 restricted stock units (RSUs), each representing an equal number of ordinary shares, to 13 employees pursuant to the Company’s 2025 Inducement Plan. The stock options and RSUs were granted as an inducement material to the individual becoming an employee of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option awards and RSUs have a grant date of June 24, 2026. The stock option awards have an exercise price of $1.66 per share, which is equal to the closing price of Autolus’ common stock on June 23, 2026. Each stock option award has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the hire date of the employee and the remainder vesting in 36 equal monthly installments thereafter. Each RSU vests in four equal annual installments. The options and RSUs are subject to the employee's continued service with Autolus through the applicable vesting dates.
About Autolus Therapeutics plc Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
What equity inducement awards did Autolus Therapeutics (AUTL) grant on June 24, 2026?
Autolus Therapeutics granted stock options for 25,420 ADSs and 87,530 RSUs to 13 employees. According to the company, these awards were issued under the 2025 Inducement Plan as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4).
What is the exercise price and term of the new Autolus (AUTL) stock options granted in June 2026?
The new Autolus stock options have a $1.66 exercise price and a ten-year term. According to the company, the price equals the June 23, 2026 closing share price, and options vest over four years, subject to continued employment with Autolus.
How do the Autolus (AUTL) inducement stock options vest for the 13 employees?
Autolus inducement stock options vest over four years, starting one year after hire. According to the company, 25% of each award vests on the first anniversary, with the remaining 75% vesting in 36 equal monthly installments, contingent on continued service.
What is the vesting schedule for the 87,530 RSUs granted by Autolus Therapeutics (AUTL)?
The 87,530 RSUs granted by Autolus vest in four equal annual installments. According to the company, each installment requires the employee to remain in service through the applicable vesting date, aligning long-term compensation with employment duration.
Why did Autolus Therapeutics (AUTL) use Nasdaq Listing Rule 5635(c)(4) for these equity grants?
Autolus used Nasdaq Listing Rule 5635(c)(4) because the awards are inducement grants tied to new employment. According to the company, the stock options and RSUs were a material inducement for 13 individuals becoming employees under its 2025 Inducement Plan.
How many total Autolus (AUTL) shares are covered by the June 2026 inducement awards?
The June 2026 inducement awards cover 25,420 ADSs in stock options and 87,530 RSUs. According to Autolus, each RSU represents one ordinary share, so the total potential share issuance from these grants is 112,950 shares, subject to vesting and exercise.
